Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4.~* For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC~* Progressed, or been intolerant to, at least one standard treatment regimen, except for participants in 1st line cohorts.~* ECOG performance status between 0 and 2~* At least 1 lesion with measurable disease at baseline~* Availability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy)~Exclusion Criteria:~* Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease~* Autoimmune disease~* Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent~* Uncontrolled CNS metastases~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Relatlimab (Type: EXPERIMENTAL): Relatlimab (BMS-986016) specified dose on specified days
- Relatlimab + Nivolumab (Type: EXPERIMENTAL): Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
- BMS-986213 (Type: EXPERIMENTAL): Relatlimab (BMS-986016) + Nivolumab (BMS-936558)

Based on this trial design, predict the completion outcome and termination type (if applicable).